Psychiatry/Psychology | Phase I Developments

Seelos Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)

Lead Product(s): Ketamine Hydrochloride

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 26, 2020

Details:

Interim data from both studies has demonstrated that doses of 30mg, 60mg, 75mg and 90mg of SLS-002 have been generally safe and well-tolerated.

Sumitomo Dainippon Pharma Co., Ltd

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

Sumitomo Dainippon, Exscientia begin study of AI based OCD drug

Lead Product(s): DSP-1181

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 03, 2020

Details:

DSP-1181 is being progressed as a long-acting and potent serotonin 5-HT1A receptor agonist, and its phase I clinical study to treat obsessive-compulsive disorder as an indication candidate.

Cerevel Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

Cerevel Therapeutics Initiates Phase 1 Clinical Trial of CVL-936, an Investigational Medicine in Development to Treat Substance Use Disorder

Lead Product(s): CVL-936

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 30, 2020

Details:

The Phase 1 study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of CVL-936 in healthy volunteers ages 18 to 50.

Sumitomo Dainippon Pharma Co., Ltd

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

Sumitomo Dainippon Pharma and Exscientia Joint Development New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Stu...

Lead Product(s): DSP-1181

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 30, 2020

Details:

Through this deal, Sumitomo Dainippon Pharma has expanded its development pipeline to treat key unmet medical needs in the Psychiatry and Neurology area.